Acute myeloid leukemia
Conditions
Interventions
Test group:G-CSF 150ug qd -13d to -8d
Decitabine 20mg/m2 qd -12d to -8d, Bu 0.8mg/kg q6h d-7 to d-4, CTX 60mg/kg d-3 to d-2
Control group:Bu 0.8mg/kg q6h d-7 to d-4, CTX 60mg/kg d-3 to d-2
Sponsors
Xinqiao Hospital, Chongqing
Eligibility
Sex/Gender
All
Age
No minimum to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with high risk AML, no limit on the gender, aged60, Estimated lifetime>3months; 3. Patients have HLA matched donor; 4. No serious impairment of important organs; Cr55%, Hb>9g/dL, Bilirubin<2.0mg/dl; 5. No other contraindication of hematopoietic stem cell transplantation; 6. Voluntary participants, informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe cardiac, renal or hepatic dysfunction; 2. Patients have other malignant cancer and must receive treatment; 3. Patients cant understand or follow study protocol due to clinical symptoms of brain dysfunction or serious mental illness; 4. Patients cant guarantee to accomplish treatment plan and follow-up; 5. Patients with severe acute hypersensitive reaction; 6. Uncontrolled active infection; 7. Patients who have been enrolled in other clinical trial; 8. Patients arent suitable for this clinical trial according to investigators judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rate of relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Leukemia free survival;rate of acute graft versus host disease;rate of chronic graft versus host disease;rate of side effects;treatment related mortality; | — |
Contacts
Public ContactXi Zhang
Xinqiao Hospital, Chongqing
Outcome results
None listed